No information is available on the use of belinostat during breastfeeding. Because belinostat is >92% bound to plasma proteins, amounts in milk are likely to be low. The manufacturer states that breastfeeding is not recommended during treatment with belinostat, and for 2 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Belinostat
CAS Registry Number
866323-14-0
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Histone Deacetylase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
